Observational studyEmerging microbes & infections2020
Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study.
Observational study in Emerging microbes & infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a study.Emerging microbes & infections · 2024Trial
- Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial.Signal transduction and targeted therapy · 2021Trial
- HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients.Signal transduction and targeted therapy · 2021Trial
- Pre-Digested Protein Enteral Nutritional Supplementation Enhances Recovery of CD4Frontiers in immunology · 2021Trial
- Dynamic prediction of HIV-related incomplete immune reconstitution: A multicenter, large cohort study using advanced joint modeling.Science advances · 2026Article
- Efficacy and safety of doravirine/lamivudine/tenofovir as initial treatment for people living with HIV in China.Antimicrobial agents and chemotherapy · 2026Article
- Five-Year Immune Recovery After ART Initiation Among PLWH Aged ≥15 Years with Baseline Immunosuppression - China, 2013-2024.China CDC weekly · 2026Article
- Determinants of immune recovery and survival in HIV late presenters: a retrospective cohort study from Southwest China.AIDS research and therapy · 2026Article
- Immune reconstitution efficacy and the risk factors of immune non-responsiveness after combined antiretroviral therapy in HIV-1 positive MSM and heterosexual population - a prospective cohort study.Immunity & ageing : I & A · 2026Article
- Immune reconstitution efficacy and associated risk factors for immunological non-response in people living with HIV during long-term antiretroviral therapy: a single-center retrospective cohort study at a tertiary care hospital in China.Frontiers in immunology · 2026Article
- GNLY+CD8+ T cells bridge premature aging and persistent inflammation in people living with HIV.Emerging microbes & infections · 2025Article
- ENO2 regulates CD4mBio · 2025Article
- Tripartite interplay: immune reconstitution dynamics in AIDS, gut microbiota, and Helicobacter pylori infection: current advances and therapeutic prospects.Gut pathogens · 2025Article
- Trends in Life Expectancy of HIV-Infected Patients Receiving Antiretroviral Therapy - China, 2013-2023.China CDC weekly · 2025Article
- A Multistate Continuous Time-Inhomogeneous Markov Model for Assessing the CD4 Count Dynamics of HIV/AIDS Patients Undergoing Antiretroviral Therapy in KwaZulu-Natal, South Africa.International journal of environmental research and public health · 2025Article
- Association of HIV low-level viremia with CD4 count recovery among persons living with HIV during antiretroviral therapy in Dehong Prefecture, Southwest China in 2008-2021: a longitudinal study.BMC infectious diseases · 2025Article
- Establishment and evaluation of a predictive model for immune reconstitution in people living with HIV after antiretroviral therapy.BMC infectious diseases · 2025Article
- Multi-omics dissection of metabolic dysregulation associated with immune recovery in people living with HIV-1.Journal of translational medicine · 2025Article
- Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using normalization of CD4 counts as the main evaluation parameter of complete immune restoration for HIV-1 patients under antiretroviral therapy (ART) might be not enough. A comprehensive evaluation system more accurately reflecting immune restoration are urgently needed. Totally, 91,805 HIV-1 patients from 17 tertiary hospitals in China during 2005-2018 were included in this study. Immune restoration and mortality were assessed. Patients initiated ART with baseline CD4 counts <50, 50-199, 200-349, 350-499, and ≥500 cells/μL, and results showed an increase in the median CD4 counts to 445 (12-year), 467 (12-year), 581 (11-year), 644 (7-year), and 768 cells/µL (5-year), as well as the CD4/CD8 ratio to 0.59 (12-year), 0.65 (12-year), 0.79 (11-year), 0.82 (7-year), 0.9 (5-year), respectively. The median CD8 count was relatively high (median range 732-845 cells/μL), regardless of the baseline CD4 counts. Furthermore, the probabilities of death in patients achieving CD4 counts ≥500 cells/μL and CD4/CD8 ratio ≥0.8 simultaneously were significantly lower than those in patients achieving either CD4 counts ≥500 cells/μL (2.77% vs 3.50%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.